Dr. Oratz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
4TH floor NYU Perlmutter Cancer Center
New York, NY 10016Phone+1 212-731-5760Fax+1 212-731-5863
Summary
- Dr. Ruth Oratz is an oncologist in New York, NY and is affiliated with NYU Langone Hospitals. She received her medical degree from Albert Einstein College of Medicine and has been in practice 35 years. She also speaks multiple languages, including French. She specializes in breast cancer, cancer genetics/cancer risk assessment.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1985 - 1988- NYU Grossman School of MedicineResidency, Internal Medicine, 1982 - 1985
Albert Einstein College of MedicineClass of 1982
Certifications & Licensure
NY State Medical License 1983 - 2025
CO State Medical License 2003 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2020
- America's Top Doctors for Cancer Castle Connolly, 2008-2020
- Top Doctors: New York Metro Area Castle Connolly, 2002, 2008-2020
- Join now to see all
Clinical Trials
- Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
- Exemestane and Cyclophosphamide for Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Publications & Presentations
PubMed
- 15 citationsSerial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.Maryann Kwa, Xiaochun Li, Yelena Novik, Ruth Oratz, Komal Jhaveri
Breast Cancer Research and Treatment. 2018-02-01 - 47 citationsEffect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.Howard S. Hochster, Leonard Liebes, James L. Speyer, Joan Sorich, B Taubes
Clinical Cancer Research. 1997-08-01 - 141 citationsPhase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.Howard S. Hochster, Leonard Liebes, James L. Speyer, Joan Sorich, Beth Taubes
Journal of Clinical Oncology. 1994-03-01
Press Mentions
Common Breast Cancer Treatments May Accelerate Aging, Study FindsOctober 17th, 2024- Many Women Underestimate Breast Density as a Risk Factor for Breast Cancer, Study ShowsJanuary 23rd, 2023
- Blood Test That Screens for 50 Cancers, Found Promising in Preliminary StudySeptember 13th, 2022
- Join now to see all
Grant Support
- Interleukin 2 + Histamine Versus Interleukin 2 In Advance Malignant MelanomaNational Center For Research Resources1999–2002
- Bryostatin 1 (NSC339555) &Cisplatin In Advanced MalignanciesNational Center For Research Resources1999–2002
- Core--Clinical Research ResourcesNational Cancer Institute1999–2000
- Core--Patient Research ResourcesNational Cancer Institute1994–1998
Professional Memberships
- Member
- Member
- Fellow
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
